跳到主要內容

林郁里副研究員

▍聯繫資訊
  • 辦公室:第七共研
  • 電話:院內分機 263170
  • Email:linyuli888@gmail.com
  • 實驗室網站:建置中

 

▍學歷
  • 國立臺灣大學醫學院 生物化學暨分子生物學研究所 博士
  • 國立臺灣大學醫學院 生物化學暨分子生物學研究所 碩士

 

林郁里副研究員
▍經歷
  • 國立臺灣大學醫學院(附設醫院)醫學研究部 助理研究員
  • 國立臺灣大學醫學院 臨床醫學研究所 博士後研究員

 

▍主要專長
  • 生物化學
  • 病毒免疫學
  • 疫苗學
  • 腫瘤免疫學

 

▍研究方向
  • 疫苗及佐劑研發
  • 抗病毒藥物研發
  • 腫瘤治療
  • 靈芝免疫調節之研究
  • 天然抗氧化物之研究

 

▍近五年論文發表
  • Chen JL, Pan CK, Huang YS, Tsai CY, Wang CW, Lin YL*, Kuo SH, Shieh MJ. Evaluation of antitumor immunity by a combination treatment of high-dose irradiation, anti-PDL1, and anti-angiogenic therapy in murine lung tumors. Cancer Immunology, Immunotherapy 70(2):391-404, 2021. DOI: 10.1007/s00262-020-02690-w.
  • Lin YL, Shih C, Cheng PY, Chin CL, Liou AT, Lee PY, Chiang BL*. A polysaccharide purified from Ganoderma lucidum acts as a potent mucosal adjuvant that promotes protective immunity against the lethal challenge with Enterovirus A71. Frontiers in Immunology 11:561758, 2020. DOI: 10.3389/fimmu.2020.561758.
  • Chen JL, Shen CW, Wang CC, Huang YS, Chen JP, Chiang CH, Lin YL, Kuo SH, Wang CW*. Impact of smoking cessation on clinical outcomes in patients with head and neck squamous cell carcinoma receiving curative chemoradiotherapy: A prospective study. Head Neck, 41(9):3201-3210, 2019. DOI: 10.1002/hed.25814.
  • Chen JL, Chang CC, Huang YS, Kuo HY, Chen TY, Wang CW, Kuo SH, Lin YL*. Persistently elevated soluble MHC class I polypeptide-related sequence A and transforming growth factor-β1 levels are poor prognostic factors in head and neck squamous cell carcinoma after definitive chemoradiotherapy. PLoS One, 13(8):e0202224, 2018. DOI: 10.1371/journal.pone.0202224.
  • Jan RH, Chen CJ, Hong YR, Lin YL*, Chen LK*. A surface antigen of Orientia tsutsugamushi activates human monocyte-derived dendritic cells via nuclear factor-kB & p38 mitogen-activated protein kinase pathways. Indian J Med Res, 148 (2): 215-224, 2018. DOI: 10.4103/ijmr.IJMR_1417_16.
  • Lin YL, Cheng PY, Chin CL, Huang LM, Lin SY, Chiang BL*. Fibroblast-stimulating lipopeptide-1 as a potential mucosal adjuvant enhances mucosal and systemic immune responses to enterovirus 71 vaccine. Vaccine, 36(29):4331-4338, 2018. DOI: 10.1016/j.vaccine.2018.05.090.
  • Lin YL, Chow YH, Huang LM, Hsieh SM, Cheng PY, Hu KC, Chiang BL*. A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge. Scientific Reports, 8(1):10713, 2018. DOI: 10.1038/s41598-018-28281-5.
  • Liu WC, Lin YL, Spearman M, Cheng PY, Butler M, Wu SC*. Influenza hemagglutinin glycoproteins with different N-glycan patterns activate dendritic cells in vitro. J Virol, 90(13):6085-6096, 2016. DOI: 10.1128/JVI.00452-16.